tirzepatide mcas and Multiple Sclerosis: Safety and Clinical Considerations Microdosing Tirzepatide (GLP-1) for MCAS:

It has been detected that DSIP (Delta Sleep-Inducing Peptide) reduced the nocturnal activity of an enzyme, NAT, and might also be involved in the modulation of adrenergic transmission

Injections, on the other hand, offer a more direct and potent alternative

Our JHU policy labs blog post this week by Mariah Bowman ties these themes together, emphasizing the need to move away from traditional antivenom production to antivenomics

I no longer have any affiliation with the bank and therefore I aim to derive a facts-based analysis, whilst any views expressed here do not represent investment advice or the views of my former employer